This is an old revision of this page, as edited by Monkbot(talk | contribs) at 16:13, 19 October 2020(Task 17: replace to-be-deprecated: |name-list-format= (3× replaced; usage: 3 of 3);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 16:13, 19 October 2020 by Monkbot(talk | contribs)(Task 17: replace to-be-deprecated: |name-list-format= (3× replaced; usage: 3 of 3);)
Its use for these indications was limited by side effects such as dry mouth and nausea, and at high doses it can cause more severe symptoms such as deliriant and hallucinogenic effects.[1] "Large doses of benactyzine in normal subjects may produce a state resembling the action of mescaline or LSD."[2]
Brand names have included: Suavitil, Phebex, Phobex, Cedad, Cevanol, Deprol, Lucidil, Morcain, Nutinal, Parasan. While there was some tentative evidence of effectiveness when combined with meprobamate, with the medication no longer available it is not clinically important.[3]
History
Benactyzine was brought to market in the US in 1957 by Merck under the tradename, Suavitil.[4]
References
^ abShorter E (December 2002). "Looking backwards: a possible new path for drug discovery in psychopharmacology". Nature Reviews. Drug Discovery. 1 (12): 1003–6. doi:10.1038/nrd964. PMID12461521. S2CID23439533.
^Fisher S (1959). Child Research In Psychopharmacology (1st ed.). Springfield, Illinois: Charles C Thomas Pub. p. 13.